Coagulants

• 

  Subject Areas on Research

  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. 
  • Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. 
  • Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. 
  • Critical role for mouse marginal zone B cells in PF4/heparin antibody production. 
  • Cryoprecipitate therapy. 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Domino liver transplantation in maple syrup urine disease: a case report and review of the literature. 
  • Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. 
  • Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation. 
  • Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. 
  • Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency. 
  • Factor X deficiency and pregnancy: preconception counselling and therapeutic options. 
  • Factor concentrates for perioperative bleeding: old drugs with new approaches. 
  • Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis. 
  • Heparin-induced decrease in circulating antithrombin-III. 
  • Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). 
  • In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. 
  • Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. 
  • Obstetric hemorrhage. 
  • Postpartum hemorrhage: when uterotonics and sutures fail. 
  • Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy. A prospective, randomized study. 
  • Progressive improvement in wound healing with increased therapy in haemophilia B mice. 
  • Reversal agents for non-vitamin K antagonist oral anticoagulants. 
  • Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? 
  • Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operations. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.